



nDatalyze Corp.

NEWS RELEASE

nDatalyze announces results of its marketing study.

Calgary, Alberta – January 26, 2022

For Immediate Release – nDatalyze Corp. (“**NDAT**” or the “**Corporation**”) (CSE: NDAT)(OTC: NDATF) is pleased to announce that the Corporation has received the final third-party marketing study analysis of YMI.

Jim Durward, President, states: "Most importantly, this analysis clearly shows that YMI is a desirable product across multiple age groups. Additionally, the analysis generated granular data related to pricing range and format, general "look&feel" and desired features. Not only was there demand for mental health predictions but also for products and services to address the predicted probabilities. This "sell-through" demand was anticipated by management and the ability largely exists within the YMI platform. Other analysis data indicates that we can roll-out YMI incrementally, with feature "bundles" consisting of various mental conditions and various pricing/subscription models. We are now awaiting a new proposal in this regard."

The Corporation believes that while Anxiety is a common mental condition affecting millions of people annually, the pandemic is causing a significant increase in population anxiety generally. With this in mind, Anxiety will be the first Condition released with Depression, PTSD, OCD, Alcoholism, BiPolar and Personality disorders being added as they emerge from their testing cycles.

About nDatalyze Corp.:

nDatalyze Corp. generates technology-based, health-related solutions. The YMI division is developing a machine-learning based, online consumer mental health application and the MLdelic division is focusing on applying machine-learning to assist in the prediction of potential benefits associated with the use of entheogenic compounds within the mental health sector. Both YMI and MLdelic are based on the Corporation's proprietary Reference Database consisting of >1200 biometric records complete with "same-time-of-day" EEG data. With installations worldwide, its Medxtractor division manufactures and sells small-scale bio-extractors that are used to extract compounds from a variety of botanical biomasses. While the Medxtractor division is currently generating cash flow, both YMI and MLdelic are in development and accordingly the Corporation cannot accurately predict if or when these applications will become cash flow generators.

FOR FURTHER INFORMATION, PLEASE CONTACT:

nDatalyze Corp.

James Durward, President and CEO

Telephone: (403) 689-3901

Email: jimd@ndatalyze.com Website: www.ndatalyze.com

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ

materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. *These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Asian and international medical products market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of hemp and hemp-related products in Asia and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.*

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.